NCT00441155 2013-05-13Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With ImatinibNovartisPhase 1 Completed14 enrolled